Xiaonan Hong

Phase II Clinical Trial on Chidamide, Rituximab and High-Dose Methotrexate (C-R-HDMTX) in Newly Diagnosed Primary CNS Lymphoma

Guangliang Chen, Jia Jin, Hui Sun, Yizhen Liu et autres

Abstract Background: Primary Central Nervous System Lymphoma (PCNSL) is an aggressive non-Hodgkin lymphoma variant confined to the central nervous system. Current treatment primarily uses high-dose methotrexate (MTX) with rituximab, but incomplete responses and relapse are common. Chidamide, an oral histone deacetylase (HDAC) …

cn (code pays fourni par la source)

Chidamide plus R‐ GDP for relapsed/refractory diffuse large B‐cell lymphoma in patients ineligible for autologous transplantation: A prospective, single‐arm, phase II study

Guangliang Chen, Kai Xue, Qunling Zhang, Zuguang Xia et autres

BACKGROUND: In relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), a negative prognosis is frequently linked to heightened epigenetic heterogeneity. Chidamide, a selective histone deacetylase inhibitor, shows promise as a targeted therapy for R/R DLBCL by targeting abnormal epigenetic changes associated with poor …

cn (code pays fourni par la source)

Phase 2 study of pegylated liposomal doxorubicin plus cyclophosphamide, vincristine/vindesine, and prednisone in newly diagnosed PTCL: 8-year results

Zuguang Xia, Fangfang Lv, Qunling Zhang, Yizhen Liu et autres

BACKGROUND: Pegylated liposomal doxorubicin (PLD) is a liposome-encapsulated form of doxorubicin with equivalent efficacy and less cardiotoxicity. This phase 2 study evaluated the efficacy and safety of the PLD-containing CHOP regimen in newly diagnosed patients with aggressive peripheral T-cell lymphomas (PTCL). METHODS: …

cn (code pays fourni par la source)

Predicting central nervous system relapse in primary breast diffuse large B-cell lymphoma using the stage-modified IPI score: A retrospective cohort study

Guangliang Chen, Pin Guo, Jin Wang, Baohua Yu et autres

Objective: The existing Central Nervous System-International Prognostic Index (CNS-IPI) provides insufficient guidance for predicting central nervous system (CNS) relapse in individuals with primary breast diffuse large B-cell lymphoma (DLBCL). This retrospective cohort study sought to examine the potential of the stage-modified IPI …

cn (code pays fourni par la source)

Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study

William Townsend, Wolfgang Hiddemann, Christian Buske, Guillaume Cartron et autres

The phase III GALLIUM trial assessed the safety and efficacy of obinutuzumab-based versus rituximab-based immunochemotherapy in patients with previously untreated follicular lymphoma (FL) or marginal zone lymphoma (MZL). At the primary analysis, the trial met its primary end point, demonstrating improvement in …

gb, de, fr, au, cn, ch (code pays fourni par la source)

Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non‐germinal centre B‐cell‐like diffuse large B‐cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial

Jun Zhu, Xiaonan Hong, Yu Qin Song, Brendan P. Hodkinson et autres

Abstract In this post hoc subgroup analysis of 200 patients enrolled in China from the phase III PHOENIX trial (N = 838, NCT01855750), addition of ibrutinib to rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP) did not improve event‐free survival (EFS) versus …

cn, us, be, nl (code pays fourni par la source)

Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera ® ) in combination with CHOP in patients with previously untreated CD20‐positive diffuse large B‐cell lymphoma: A randomized, single‐blind, phase III clinical trial

Yuankai Shi, Qingyuan Zhang, Xiaonan Hong, Zhen Wang et autres

Abstract This study compared the efficacy, safety and immunogenicity of ripertamab (SCT400) and rituximab (Mabthera ® ) combined with CHOP as the first‐line treatment for Chinese patients with CD20‐positive diffuse large B cell lymphoma (DLBCL). This is a randomized, patient‐blind, multicenter, active‐control, …

cn, hk (code pays fourni par la source)

Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma

Michael Wang, Wojciech Jurczak, Mats Jerkeman, Judith Trotman et autres

BACKGROUND: Ibrutinib, a Bruton's tyrosine kinase inhibitor, may have clinical benefit when administered in combination with bendamustine and rituximab and followed by rituximab maintenance therapy in older patients with untreated mantle-cell lymphoma. METHODS: We randomly assigned patients 65 years of age or …

hu (code pays fourni par la source)

Hexokinase II expression as a prognostic marker in diffuse large B-cell lymphoma: pre- and post-rituximab era

Jia Jin, Ailing Gui, Guangliang Chen, Yizhen Liu et autres

cn (code pays fourni par la source)

Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial

Jia Jin, Dongmei Ji, Zuguang Xia, Kai Xue et autres

BACKGROUND: R-CHOP with or without radiotherapy is the standard treatment for limited-stage diffuse large B-cell lymphoma (DLBCL). To prevent overtreatment, we assessed whether four cycles of CHOP plus six applications of rituximab was adequate with negative interim PET/CT and the role of …

cn, in (code pays fourni par la source)

Prognostic significance of clinical characteristics and 18 Fluorodeoxyglucose-positron emission tomography/computed tomography quantitative parameters in patients with primary mediastinal B-cell lymphoma

Yizhen Liu, Jinjin Jiang, Lianfang Liu, Zezhou Wang et autres

Objective Primary mediastinal B-cell lymphoma (PMBCL) lacks standard treatment regimens. This study aimed to identify the disease’s clinical features and prognostic factors. Methods This retrospective study included 56 patients with PMBCL. Patient demographic details and clinicopathological characteristics were summarized, and their effects …

cn (code pays fourni par la source)

Efficacy and Safety of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody (SCT400) Combined with CHOP in Patients with Treatment-Naïve Diffuse Large B-Cell Lymphoma: A Multicenter, Randomized, Single-Blind, Parallel Active-Controlled, Phase III Study

Yuankai Shi, Qingyuan Zhang, Xiaonan Hong, Zhen Wang et autres

Abstract Background: SCT400 is a recombinant, human-mouse chimeric anti-CD20 IgG1 monoclonal antibody and has the same variable regions and antigen-binding site as rituximab. SCT400 has the heavy and κ light chain constant regions of human IgG1 allotype G1m (1,17), which is common …

cn, hk (code pays fourni par la source)